

Antibiotic Resistance Pattern of Isolates in Intensive Care Unit and Source of Nosocomial Infection in a Tertiary Care Hospital, Dhaka, Bangladesh

Mirza Nazim Uddin¹, NurunNahar Mawla², Zahidul Hasan³, Faridul Islam⁴, Anowar Hossain⁵

¹MBBS, MRCP (Medicine), Director, Medical services, Square Hospitals Ltd

²MBBS, M Phil (Microbiology), Associate Consultant, Microbiology Laboratory, Square Hospitals Ltd

³MBBS, M Phil (Microbiology) Consultant, Microbiology Laboratory, Square Hospitals Ltd

⁴MS (Microbiology), Medical Laboratory Scientist Square Hospitals Ltd

⁵MBBS, MCPS, MCAP, FCAP (Clinical Pathology), Head, Laboratory Operation, Square Hospitals Ltd

Abstract: ***Background:** Infections with resistance bacteria threatens the effectiveness of antibiotic treatment with increased morbidity, mortality and hospital costs. Rapid emergence of multi-drug resistance necessitates monitoring microbial isolates with their resistance pattern. During 2015-16, this study conducted in Square hospital ICU to see pattern of pathogens, their antimicrobial resistance and presence of MRSA, ESBL and CRE in nosocomial infections. **Methods:** Specimens from ICU patients processed for isolation, identification, tested antimicrobial resistance and production of ESBL, CRE and MRSA following standard methods. Admitted patients were monitored and data analyzed for pattern of hospital-acquired infections. **Results:** Of 2,447 pathogens, majority yielded from tracheal aspirates (37%) compared to others. Among pathogens, Klebsiella were 21.6%, E. coli 12%, Pseudomonas 9.9% and Acinetobacter spp 9.8%; while Staphylococci were 8.3%, Enterococci 3.4%, Pneumococci 2% and Candida were 13%. Overall 78% E. coli were resistant to multiple drugs; of which 82% resistant to cefuroxime, 75% to amoxiclav and ciprofloxacin each, 69% to ceftixime, 67% to ceftriaxone and 66% to ceftipime. Majority Klebsiella were resistant to common antibiotics, except meropenem (50%). About 40% Pseudomonas and Acinetobacter were resistant to common antibiotics except colistin and polymyxin B. About 58% of E. coli and 24% Klebsiella produced ESBL, with 48% resistant to carbapenem. Penicillin and amoxicillin resistance were 90% among gram positive bacteria and MRSA Producing Staphylococci was 47% with no resistance to vancomycin. Among 277 hospital-acquired infections, Ventilator associated pneumonia (VAP) was 56% followed by 23.1% UTI and 10.5% BSI. **Conclusion:** Emergence of MDR bacteria among ICU patients is a global problem as they contract hospital-acquired infections more commonly from foci within hospitals. Higher prevalence of MDR infection in ICU of SHL is not an exception. Challenges remain in treating patients with CRE, ESBL and MRSA infections. Strengthening antimicrobial stewardship, monitoring effectiveness of antibiotic usage and infection control program could reduce this critical problem.*

Keywords: Antimicrobial resistance, Hospital acquired infection, Intensive care unit.

1. Introduction

The Intensive Care Unit (ICU) is commonly known as the epicenter of infections, because of its patient populations both in the medical intensive care unit (MICU) and the surgical intensive care unit (SICU) who are extremely vulnerable and immunocompromised. Once immunodeficient state develops in patients, they are very much prone to colonize and harbor the opportunistic or virulent pathogens carrying antimicrobial resistant genes. These patients are slower in shedding out the pathogens and in combating the colonized or invading organisms in preventing disease development [1]. Besides, greater numbers of ICU patients are at high risk of acquiring infection through the use of multiple procedures including invasive devices that compromise normal flora of skin and mucosal barriers [2]. An estimate of the prevalence of Infection in European Intensive Care (EPIIC) is about 51% among 12,796 patients admitted in 1265 ICUs of 75 countries [3]. The ICU is thus considered as a factory for creating, disseminating and amplifying antimicrobial resistance[4] which not only creates a major problem in

treating infections but also contributing in emergence of multi-drug-resistant (MDR) pathogens. The development of MDR infection adds the clinical and economic burden to the individual and to the hospital authority [5]. The possible reasons of rising antibiotic resistance underlies on their irrational use, inappropriate prescribing and self-medication through over-the-counter drugs that contributed increased consumption of non-prescribed antibiotics. These factors led to the selective pressure of antibiotics resulting ineffectiveness of those antibiotics with an increased morbidity and mortality [6]. In addition, ICU patients are exposed to a greater hazard of contamination and cross infection that contributes to the development of increasing antibiotic resistance. The antibiotic resistance pattern, however, is not a static phenomenon, thus necessitates regular monitoring and updating of antibiogram as the recent resistance pattern helps the physicians in selecting the appropriate antimicrobials for better case management [7]. It is also required to guide the judicious uses of antibiotics throughout the institution and helps in developing the antimicrobial prescribing policy.

The ICU patients are thus at particular risk of acquiring hospital acquired infection (HAI) (also called nosocomial infections). This infection is usually develops 48 hours after hospital admission or after discharge that was not present at the time of admission [8]. The reported prevalence of HAI is about 30% in the USA [9]. The attributed pathogens of HAI are bacterial, viral and fungal microorganisms and the ICU patients are 5-10 times higher risks than those at general wards [10]. Currently, the most concerned resistant microorganisms in ICU are gram-positive methicillin-(oxacillin)-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant Enterococci (VRE) [11]. Of the gram-negative bacteria, the resistance is usually due to extended-spectrum Beta-lactamases (ESBLs) and Carbapenem-resistant enterobacteriaceae (CRE) that includes *Klebsiella pneumoniae*, *Escherichia coli*, *Enterobacter* and *Proteus* species. The prevalence of MDR in *Pseudomonas* and *Acinetobacter* are also high in ICU patients [12]. The EPIIC study reported about 50% MRSA isolates in Europe and 65% in America [3], while the National Nosocomial Infection Surveillance (NNIS, USA) study reported 27% fluoroquinolone-resistance in *Pseudomonas* and 18% to imipenem [13]. The National Healthcare Network (NHN) in Dhaka reported 43% MRSA and 20% ESBL producing Enterobacteriaceae [14,15]. The reported risk factors for infection and/or colonization with MRSA, ESBL, and CRE producing bacteria are the past exposure or prolonged ICU-hospitalization, prior and prolonged use of antimicrobials, indwelling devices, chronic underlying conditions, surgical wounds, mechanical ventilation, advanced age and cross-contamination [16].

Antibiotic resistance among pathogens in hospital ICUs worldwide has been increasing with varying degrees between the countries. A local surveillance program is thus required to generate local data set that would guide prudent use of antibiotics and in developing prescribing policy for guiding appropriate antimicrobial therapy in treating ICU infections [17, 18]. Routine surveillance using multi-samples (series) cultures will help physicians in selecting empirical therapy with higher success rate and thus save the last-line antibiotic agents. The general aim of this study was to collect and analyze data in order to update information on microbial pathogens and the antimicrobial susceptibility from the Square Hospital (SHL) ICU for a period of two years between January 2015 and December 2016; and the specific objective was to see the trend of antimicrobial resistance including the presence or absence of MRSA, ESBL and CRE in clinical isolates obtained from patients and define the main and common source and pattern of nosocomial infections. The SHL is a 450-bedded tertiary care hospital located at the centre of the Dhaka city, Bangladesh.

2. Materials & Methods

Study place and samples: This retrospective study was conducted in Microbiology Laboratory of Square Hospital Ltd (SHL) that processed the clinical samples for microbial culture from patients who were admitted in the ICU, SHL between January 2015 and December 2016.

Microbial isolates: Clinical specimens of blood, tracheal aspirates, sputum, urine, wound swab, pus and broncho-alveolar lavages obtained from ICU patients were processed for microbial culture, isolation, identification and antimicrobial susceptibility testing following standard method.¹⁹ Briefly, all specimens were inoculated onto blood agar (BA), chocolate agar (CA) and MacConkey agar (MCA) plates, and were incubated at 37°C for 18-24 hours. Blood cultures were processed in an automated blood culture machine (Bact Alert 3D, bioMerieux, France) that signals positive growth which were then sub-cultured onto the above bacterial culture media. The positive growth of suspected pathogenic bacteria were further characterized for identification by standard microbiological procedures including colony morphology, Gram stain, biochemical reaction, serologic tests and antimicrobial susceptibility testing etc [19].

Antimicrobial susceptibility test (AST): The AST was carried out by Kirby-Bauer method[20] against a selected panel of antibiotics (Table-1) discs for gram positive and gram negative organisms. In brief, suspensions of the test organisms were made in Muller-Hinton broth, turbidity adjusted to McFarland 0.5 standards, incubated for 2 hours and then bacterial lawn was made on Mueller Hinton Agar (MHA) plate onto which the antibiotic disks were applied. The plates were incubated at 37°C for 24 hours, screened and measured the diameter of zone of inhibition and interpreted as susceptible, intermediate and resistant according to Clinical Laboratory Standard Institute (CLSI) guidelines [20].

Table 1: List of antimicrobials used in the study

| Name of Antimicrobials | | | |
|------------------------|----------------------|----|--------------------|
| 1 | Penicillin | 14 | Amoxiclav |
| 2 | Amoxicillin | 15 | Levofloxacin |
| 3 | Ceftriaxone | 16 | Cefixime |
| 4 | Cefuroxime | 17 | Cefepime |
| 5 | Cefoxitin | 18 | Amikacin |
| 6 | Gentamicin | 19 | Tobramycin |
| 7 | Ciprofloxacin | 20 | Pipercillin |
| 8 | Cotrimoxazole | 21 | Pip-tazo |
| 9 | Clindamycin | 22 | Meropenem |
| 10 | Rifampicin | 23 | Collistin |
| 11 | Linezolid | 24 | Polymixin B |
| 12 | Vancomycin | 25 | Aztreonam |
| 13 | Tetracycline | 26 | Minocycline |

Resistance biomarkers: The extended spectrum β -lactamase (ESBL) was detected in Enterobacteriaceae, such as, *E. coli*, *Klebsiella*, *Enterobacter* and *Citrobacter* after inoculating onto MHA media with amoxyclav disc in the centre while ceftazidime, ceftriaxone, cefixime and cefuroxime discs were placed peripherally at equi-distant away from amoxyclav disc. Formation of band between amoxyclav and any other discs were considered as ESBL positive [13,21]. These organisms were also regarded as Carbapenem Resistant Enterobacteriaceae (CRE) positive when zone diameter of meropenem was <19 mm [20]. For detecting MRSA, suspensions of *S. aureus* were inoculated onto MHA plate onto which cefoxitin disc was placed and zone diameter of <21 mm referred to cefoxitin resistance which was regarded as MRSA [15].

3. Results

During 2015-16, a total of 2,447 pathogens were isolated from seven (07) categories of samples collected from patients in Square hospital intensive care unit (ICU). The highest number of isolates were found from tracheal aspirates (37%) followed by sputum (24.8%), urine (15.7%) and blood (14.5%) and the isolates from wound swab, broncho-alveolar lavage and pus specimens were below 5% (Table 2).

Table 2: Categories of specimens submitted in 2015 -2016

| Specimens | Total Positive Growth | Percent (%) |
|-------------------|-----------------------|--------------|
| Tracheal aspirate | 906 | 37.0 |
| Sputum | 607 | 24.8 |
| Urine | 384 | 15.7 |
| Blood | 355 | 14.5 |
| Wound swab | 89 | 3.6 |
| Broncho-lavage | 60 | 2.5 |
| Pus | 46 | 1.9 |
| TOTAL | 2,447 | 100.0 |

Distribution of 2,447 ICU patients by age and gender is shown in Table 3. The majority of patients were over 30 years of age (93.0%). By age group, the highest number of patients however, were above 60 yrs (58.2%), followed by 46-60 years (23.8%). Of total isolates recovered from patients irrespective of the age group, 56.3% were yielded from males and 43.7% from females with male: female ratio being 1.3:1.

Table 3: Distribution of patients by Age and gender

| Age | Male N (%) | Female N (%) | Total N (%) |
|--------------|---------------------|---------------------|--------------------|
| 0-15 | 2(0.1) | 2(0.2) | 4(0.2) |
| 16-30 | 78(5.7) | 99(9.3) | 177(7.2) |
| 31-45 | 157(11.4) | 102(9.5) | 259(10.6) |
| 46-60 | 330(24) | 253(23.6) | 583(23.8) |
| >60 | 810(58.8) | 614(57.4) | 1424(58.2) |
| Total | 1,377 (56.3) | 1,070 (43.7) | 2,447 (100) |

The more commonly isolated microbial agents in this study are shown in Table 4. The gram negative organisms was more frequently isolated (63.7%), of which Klebsiella was found in higher number (21.6%) followed by E. coli (12%), Pseudomonas (9.9%) and Acinetobacter (9.8%). The other gram negative isolates such as Proteus, Stenotrophomonas and Burkholderia were less frequently isolated (1.9 to 2.5%).

Table 4: Frequency and type of Isolates in ICU: 2015-2016

| Organisms | Positive growth, (n=2447) | Percentage (%) |
|------------------------|---------------------------|----------------|
| Enterobacteriaceae | | |
| E. coli | 293 | 12.0 |
| Klebsiella | 528 | 21.6 |
| Enterobacter | 75 | 3.1 |
| Proteus | 47 | 1.9 |
| Citrobacter | 7 | 0.3 |
| Serratia | 10 | 0.4 |
| Subtotal | 960 | 39.3 |
| Non-Enterobacteriaceae | | |

| | | |
|----------------------|-------------|------------|
| Pseudomonas | 241 | 9.9 |
| Acinetobacter | 240 | 9.8 |
| Burkholderiacephacia | 56 | 2.3 |
| Stenotrophomonas | 60 | 2.5 |
| Aeromonas | 2 | 0.1 |
| Subtotal | 599 | 24.5 |
| Gram Positive cocci | | |
| Staph.aureus | 202 | 8.3 |
| CoagNeg Staph | 203 | 8.3 |
| Enterococcus sp | 84 | 3.4 |
| Strep pneumonia | 49 | 2.0 |
| Strep.sp | 13 | 0.5 |
| Subtotal | 551 | 22.6 |
| Fungus | | |
| Candida | 317 | 13 |
| Aspergillus | 20 | 0.8 |
| Subtotal | 337 | 13.8 |
| Total | 2447 | 100 |

Among the gram positive bacteria, both the Staphylococcus aureus and Coagulase negative Staphylococci together constituted 8.3%, while others such as, Enterococcus, Streptococcus pneumoniae and Streptococcus species were less commonly isolated (0.5 to 2 and 3.4% respectively). Of the fungal infection, Candida sp was the predominant isolates (13%) followed by Aspergillus (0.8%).

The tracheal aspirates and blood were the two predominant specimens (44.7%) obtained from ICU patients. The types of microbial pathogens isolated from tracheal aspirates and blood during the study period of two years (2015-16) is shown in Figure 1.




Figure 1: Pattern of microbial isolates from tracheal aspirates (T/A) and blood samples: 2015-16

A higher number of growth of both gram positive and negative organisms were found in tracheal aspirates than from blood; while Coagulase negative Staphylococcus (CoNS) was more frequently seen among blood isolates. Of total 780 tracheal aspirates, Klebsiella was the most frequently isolated (28%) followed by Acinetobacter (18%), Pseudomonas (14%) and Staphylococcus aureus (13%). Among the the total of 314 positive blood isolates the CoNS was found by the highest number (36%), followed by E. coli (15%) and Klebsiella (14%). The antimicrobial resistance pattern of common gram negative organisms obtained in this study is shown in table 5.

Table 5: Resistance pattern of common Gram negative organisms at ICU, SHL: 2015-16

| Antibiotics | <i>E.coli</i> (N= 293) | <i>Klebs</i> (N= 528) | <i>Enterobac</i> (N= 75) | <i>Prot</i> (N= 47) | <i>Acinato</i> (N= 240) | <i>Pseudo</i> (N= 241) | <i>Steno</i> (N= 60) | <i>Burk</i> (N= 56) |
|--------------|---------------------------|--------------------------|-----------------------------|---------------------|----------------------------|---------------------------|-------------------------|------------------------|
| Amoxiclav | 75 | 81 | 59 | 68 | - | - | - | - |
| Cefuroxime | 78 | 82 | 60 | 62 | - | - | - | - |
| Cefixime | 69 | 79 | 32 | 28 | - | - | - | - |
| Ceftriaxone | 67 | 77 | 20 | 17 | - | - | - | - |
| Cefepime | 66 | 77 | 16 | 19 | 96 | 36 | - | - |
| Gentamicin | 33 | 50 | 13 | 25 | 89 | 47 | - | - |
| Amikacin | 14 | 53 | 09 | 25 | 92 | 37 | - | - |
| Cotrimoxa | 57 | 74 | 21 | 64 | 86 | - | 42 | 39 |
| Ciprofloxa | 75 | 78 | 17 | 25 | - | - | - | - |
| Levofloxa | - | - | - | - | 85 | 49 | 40 | - |
| Tobramycin | - | - | - | - | 90 | 48 | - | - |
| Piperacillin | - | - | - | - | 96 | 37 | - | - |
| Pip-tazo | 27 | 59 | 08 | 02 | 97 | 24 | 18 | 05 |
| Meropenem | 07 | 50 | 05 | 04 | 89 | 40 | 99 | 20 |
| Collistin | 00 | 0.6 | 00 | - | 0.8 | 00 | - | - |
| Polymixin B | 01 | 1.5 | 00 | - | 1.6 | 00 | - | - |
| Minocycline | - | - | - | - | 40 | - | 08 | 16 |
| Ceftazidime | - | - | - | - | 95 | 39 | 65 | 18 |

Resistant organisms are distributed in relative frequency (%).

The majority of the *E. coli* isolates (78%) were found resistant against cefuroxime; while 75% were resistant to both amoxyclav and ciprofloxacin followed by cefixime (69%), ceftriaxone (67%) and cefepime (66%). About 82% of *Klebsiella* isolates were resistant to cefuroxime, 81% to amoxiclav, 79% to cefixime, 78% to ciprofloxacin, 77% to both ceftriaxone and cefepime, 59% to piperacillin-tazobactam, 53% to amikacin and 50% to meropenem. The isolates of *Acinetobacter* species showed 97% resistance to piperacillin-tazobactam, 96% to cefepime and piperacillin, 89% to meropenem and gentamycin, 92% to amikacin and 90% to tobramycin. Both the *Enterobacter* and *Proteus* species showed around 60% resistance to amoxiclav and cefuroxime, while that of *Pseudomonas*, *Stenotrophomonas* and *Burkholderia* species showed low level resistance to different antibiotics; while *Stenotrophomonas* exceptionally showed 99% resistance to meropenem.

Table 6 showed the resistance pattern of gram-positive isolates against various antibiotics during the study period of 2015-2016.

Table 6: Antibiotic Resistance exhibited by gram positive organisms in SHL: 2015-16

| Antibiotics | <i>Staph. aureus</i> (N= 202) | <i>Coag. Neg Staph</i> (N= 203) | <i>Enterococcus sp.</i> (N= 84) | <i>Strept. pneumo</i> (N=49) |
|---------------|----------------------------------|------------------------------------|------------------------------------|---------------------------------|
| Penicillin | 91 | 92 | 83 | 22 |
| Amoxicillin | 90 | 92 | 63 | 22 |
| Ceftriaxone | - | - | - | 02 |
| Cefuroxime | 47 | 61 | - | - |
| Cefoxitin | 47 | 62 | - | - |
| Gentamicin | 23 | 50 | 83 | - |
| Ciprofloxacin | 60 | 66 | 79 | 51 |
| Cotrimoxazole | 25 | 56 | - | - |
| Clindamycin | - | - | - | 39 |
| Rifampicin | 32 | 25 | - | 10 |
| Linezolid | 0.5 | 03 | 00 | 00 |
| Vancomycin | 00 | 00 | 00 | 00 |
| Tetracycline | - | 43 | 76 | 65 |

Resistant organisms are distributed in relative frequency (%).

Both *Staphylococcus aureus* and Coagulase negative *Staphylococcus* (CoNS) contributed >90% resistant against penicillin and amoxicillin, while *Streptococcus pneumoniae* showed lower resistance (22%). In contrast, *Enterococcus* isolates had 83% resistance to penicillin and 63% to amoxicillin. *Staphylococcus aureus* showed less resistance to cefuroxime, cotrimoxazole, gentamicin, rifampicin and linezolid and surprisingly about 100% showed sensitive to Vancomycin. Resistance rate of Coagulase negative *Staphylococcus*, and *Enterococcus* to different antibiotics were found high, but >60% of *Streptococcus pneumoniae* showed less resistance.

The figure 2 below showed the distribution and relative frequency of the isolates producing ESBL, CRE and MRSA which are usually considered MDR pathogens.

Among MDR organisms, ESBL, CRE and MRSA are found predominantly in the ICU during the study period of two years. Of ESBL producing bacteria, 58% were *E. coli* and 24% *Klebsiella*. No ESBL was detected in *Acinetobacter*. Most of the *Acinetobacter* (89%) were however, found positive for CRE followed by *Klebsiella* (48%). A lesser number of *E. coli* (5%) has shown to be CRE producer. The MRSA was detected (47%) among the 202 *Staphylococcus aureus* isolates.




Figure 2: Frequency of ESBL, CRE and MRSA among gram-positive and gram-negative isolates

The study detected a total of 277 ICU-associated infections from different sources and devices during 2015-2016 (Figure 3). Among the important sources, ventilator associated pneumonia (VAP) was the highest in number (56%) followed by catheter associated urinary tract infection (23.1%), bloodstream infection (10.5%) and respiratory tract infections (7.9%). The rest of the patients and isolates were detected from surgical site infections (2.2%) and without catheter urinary tract infections (0.4%).




Figure 3: Pattern of Hospital Acquired Infection (HAI) in ICU by source during 2015-2016 (n= 277)

4. Discussion

Infection and antibiotic treatment have transformed modern medicine. However, sepsis is still a leading cause of hospital ICU admissions and makes up a significant number of intensive care stays. The ICU patients are usually immune-deficient. They acquired infection either from community source or infected after admissions. In our country, antibiotic prescribing policy is absent and rampant use of antibiotics is very common due to over-the-counter availability. Many of the patients are thus exposed to antibiotics before admission in ICU, or were administered after admission. Blood culture positivity is thus delayed due to presence of antimicrobial substances which has been associated with worse outcome for sepsis patients on inadequate empirical therapy. Such immune-deficient patients are critically ill and favour the emergence of multidrug-resistant pathogens by adopting one or other suitable mechanisms. Firstly, antibiotics may modify intestinal flora leading to colonization by the bacteria carrying resistant genes to important antibiotics, such as, cephalosporin, fluoroquinolone, vancomycin [22, 23]; Secondly, degrading antibiotics by releasing beta-lactamase enzymes; thirdly, pumping out of the administered antibiotics and the fourth is by changing the antibiotic target molecule by the pathogens. Additionally, ICU presents an environment in which, antimicrobial resistance propagation is accelerated through the frequent and prolonged use of antibiotics, cross infections and transmission of resistant or MDR genes. However, associated drug resistance genes or its mechanism were not studied for this report. Current study observed that more than half of all clinical isolates were obtained from respiratory samples (tracheal aspirates, sputum, broncho-alveolar lavage), and the

remaining from urine, blood and wound swab or pus which mimics findings of another study [24]. As like in many other countries, main source of respiratory tract infections in our ICU could be attributed to the most of patients who were on assisted ventilation. With regard to the clinical isolates, the present study is closely consistent with a US based study [25] that noted the gram-negative bacilli infections in ICUs predominated by Klebsiella (14.2%), E. coli (18.8%) and Pseudomonas (22.2%) including Acinetobacter. The most common gram-positive isolates reported from our ICU were Staphylococcus aureus, Coagulase-negative Staphylococcus, Enterococcus and Streptococcus pneumoniae as was documented earlier [26].

Antibiotic resistance and emergence of MDR is a global concern. The present study noted that gram negative bacilli encoded more resistance to fluoroquinolone specially among E. coli (75%), Klebsiella (78%) and Pseudomonas (49%), which is consistent with other reports [25, 27] and is reflecting an increasingly inappropriate usage of fluoroquinolone. It is also consistent with previous studies [25, 27] that showed comparatively less resistance among gram-negative bacilli to gentamicin, amikacin, piperacillin-tazobactam and meropenem. Acinetobacter species are usually inherits resistant to cephalosporin, penicillin and aminoglycoside [24]. Carbapenem was the most active drug against Acinetobacterspp, but in recent years its increasing resistance creates limited treatment options in many institutes [28]. A similar finding of about 89% Carbapenem resistant Acinetobacterspp noted in this study is a great concern and highly alarming. On the other hand, all gram positive cocci are still 100% sensitive to vancomycin, the only antibiotic remains in hand and to be preserved as the last-line therapy. In contrast, they were found highly resistance to penicillin and amoxicillin which is similar to other national studies [29, 30].

The great concern explicitly expressed in the present study with regard to the development of MDR organisms that included CRE positive Klebsiella, ESBL producing E. coli, MRSA producing Staphylococci and multi-resistant Acinetobacter. The KPC (Klebsiella pneumonia carbapenemase) producing Enterobacteriaceae specially by Klebsiella pneumoniae are noteworthy, because KPC beta-lactamases induce resistance to virtually all beta-lactam antibiotics; and many strains of Enterobacteriaceae were already reported to have induced resistance among many non-beta-lactam antibiotics as well [30]. The two studies [31,32] on ESBL producing E. coli indicated a significantly higher rate in India than that in Bangladesh (72.3 vs 43.2%). The Indian study also reported 51.28% Enterobacter spp while Bangladesh one noted 39.5% Klebsiella as ESBL producers. The present study, however, in general found comparatively a lesser number of ESBL producing organisms. Note withstanding, still ESBL producing pathogens pose a threat as these enzymes encode more resistance against many classes of antibiotics leading to treatment failures. A comparable picture of MRSA (47%) was found between this study in Bangladesh and that of ICUs in Thailand [33]. However, treatment of MRSA infected patient depends only on Vancomycin. Another concern is Acinetobacterspp that the most antibiotics becoming ineffective due to its increasing resistance to

ceftazidime (95%), amikacin (92%), meropenem (94%) and piperacillin-tazobactam (97%) which are consistent with surveillance study of antibiotic resistance pattern in ICUs in turk [34].

The present study noted that the most common HAI are the VAP-associated infections (56%) which are consistent with other studies [39], but the frequency of VAP associated reports varies between 9% to 18% and 21% [35-37]. The catheter-associated infections (23.1%) contributed among the most of nosocomial UTIs, while NNIS reported a 20-30% of nosocomial infections in ICUs due to UTIs [38]. The frequency of blood stream infection in this study was 10.5% which is far less compared to 27% found in other study [37]. However, critically ill patients constitute major foci/reservoirs of multi-resistant organisms and shown to have attributed in spread of multidrug resistance among patients in ICUs, and had been a source of the majority outbreaks of nosocomial infections with MDR organisms. Broad-spectrum empiric antimicrobial therapy is usually found effective in severe infections of ICU patients who were infected by both the gram-positive and gram-negative bacteria. But the absence of information on drug resistance is an impediment to select appropriate alternative antibiotics to be administered in correct dosage and duration. It is noteworthy that the ICU patients are also at risk of acquiring invasive candidiasis because of their immunocompromised condition. Early antifungal therapy in these cases should be considered where appropriate.

Most of the pathogenic microorganisms isolated in this study were resistant against two or more of the commonly used antibiotics (MDR). In Bangladesh and the other resource-limited countries new and effective drug is hardly available, which creates an obstructing hurdle and difficulties in treating patients with MDR. In order to contain and overcome this problem, it is suggested to have routine surveillance for MDR pathogens and antibiotic susceptibility to generate a data base that could be useful in decision-making process of empirical therapy and in formulating antimicrobials prescribing policy for prudent and rational use of initial antimicrobial therapy while preserving the last-line antibiotic agents.

5. Conclusion

Infection In the ICU by both the MDR and non-MDR pathogens require longer stay in the hospital day and imposing not only economic burden but also a concern of added challenge of severe infections from ESBL, CRE, MRSA producing organisms. A concerned global commitment to the intelligent use of antimicrobials, better program of antibiotic stewardship, effective infection control and development of more alternative but effective antimicrobials are desperately needed.

6. Acknowledgement

We sincerely acknowledge and express our gratitude for the encouragement and support provided by the ICU authority and medical services of SHL, all staff of microbiology laboratory for helping in accumulating data. We greatly acknowledge the assistance provided in analyzing the data

and repeatedly editing the manuscript in spite of extreme workload.

References

- [1] Hossain MA, Hasan KZ, Albert MJ. Shigella carriers among non-diarrhoeal children in an endemic area of Shigellosis in Bangladesh. *Trop Geog Med.*46(1)40-42; 1994.
- [2] Marwick C, Davey P: Care bundles: the holy grail of infectious risk management in hospital? *Curr Opin Infect Dis.* 22:364-369; 2009.
- [3] Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K: International study of the prevalence and outcomes of infection in intensive care units. *JAMA.* 302: 2323-2329; 2009.
- [4] Carlet J, Ben Ali A, Tabah A, Willems V, Phillippart F, Chafine A, Garrouste-Orgeas M, Misset B: Multidrug resistant infections in the ICU: mechanisms, prevention and treatment. In *25 Years of Progress and Innovation in Intensive Care Medicine.* Edited by: Kuhien R, Moreno R, Ranieri VM, Rhodes A. Berlin, Germany: MedizinischWissenschaftlicheVerlagsgesellschaft. 199-211; 2007.
- [5] Salgado CD, O Grady N, Farr BM: Prevention and control of antimicrobial resistant infections in intensive care patients. *Crit Care Med.* 33: 2373-2382; 2005.
- [6] Klevens RM, Edwards JR, Richards CL, Horan TC, Gaynes RP, Pollock DA, Cardo DM. Estimating health-care associated infections and deaths in U.S. hospitals, 2002. *Public Health Rep.* 122: 160-166; 2007.
- [7] Levin PD, Fowler RA, Guest C, Sidbald WJ, Kiss A, Simor AE. Risk factors associated with resistance to ciprofloxacin in clinical bacterial isolates from intensive care unit patients. *Infect. Control Hosp. Epidemiol.* 28: 331-336; 2007.
- [8] Costantini M, Donisi PM, Turrin MG, Diana L. Hospital acquired infection surveillance and control in intensive care services: Results of an incidence study. *Eur J Epidemiol.* 3:347-55; 1987.
- [9] Craven DE, Kunches LM, Lichtenberg DA, Kollisch NR, Barry, MA, Heeren TC et al. Nosocomial infection and fatality in medical and surgical intensive care unit patients. *Arch Intern Med.* 148(5): 1161-8; 1988.
- [10] Shaikh JM, Devrajani BR, Shah Ali SZ, Akhund T, Bibi I: Frequency, pattern and etiology of nosocomial infection in intensive care unit: An experience at a tertiary care hospital. *J Ayub Med Coll Abbottabad.* 20(4): 37-40; 2008.
- [11] Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J: Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. *Clin Infect Dis.* 48: 1-12; 2009.
- [12] Jones RN: Resistance patterns among nosocomial pathogens: trends over the past few years. *Chest.* 119:3975-4045; 2001.
- [13] Moland ES, Hanson ND, Black JA, Hossain A, Song W and Thomson KS. Prevalence of newer beta-lactamases in gram-negative clinical isolates collected in the United States from 2001 to 2002. *J. Clin. Microbiol.* 44: 3318-3324; 2006.

- [14] Gilbert M, Macdonald J, Gregson D, Siushansian J, Zhang K, Elsayed S, Laupland K, et al. Outbreak in Alberta of community-acquired (USA300) methicillin-resistant *Staphylococcus aureus* in people with a history of drug use, homelessness and incarceration. *Can. Med. Assoc. J.* 175:149-154; 2006.
- [15] Huang SS, Yokoe DS, Hinrichsen VL, Spurchise LS, Datta R, Miroshnik I, and Platt R. Impact of routine intensive care unit surveillance cultures and resultant barrier precautions on hospital-wide methicillin-resistant *Staphylococcus aureus* bacteremia. *Clin. Infect. Dis.* 43:971-978; 2006.
- [16] Clark NM, Hershberger E, Zervosc MJ, Lynch JP: Antimicrobial resistance among gram-positive organisms in the intensive care unit. *Curr Opin Crit Care.* 9:403-412; 2003.
- [17] Porzecanski I, and Bowton DL. Diagnosis and treatment of ventilator-associated pneumonia. *Chest*, 2006; 130, 597-604.
- [18] Park, D, R. Antimicrobial treatment of ventilator-associated pneumonia. *Respir. Care.* 50, 932-952; 2005.
- [19] Murray, P. R., Baron, E.J., Tenover, F.C., and Tenover, F.C., et al. (ed.). *Manual of Clinical Microbiology*, 7th ed. ASM Press., (1999); Washington, D.C.
- [20] National Committee for clinical Laboratory Standards/Clinical and Laboratory Standards Institute (NCCLS/CLSI). *Performance Standards for Antimicrobial Disk Susceptibility Tests.* NCCLS document, 2003; M2-A8, Wayne, Pa.
- [21] Mulvey, M.R., Bryce, E., Boyd, D., Ofner-Agostini, M., Christianson, S., Simor, A.E., Paton, S., and The Canadian Hospital Epidemiology Committee of The Canadian Nosocomial Infection Surveillance Program, Health Canada. Amber class A extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella* spp. in Canadian hospitals. *Antimicrob. Agents Chemother.* 48:1204-1214; 2004.
- [22] Pallares R, Pujol M, Pena C et al. Cephalosporins as risk factors for nosocomial *Enterococcus faecalis* bacteremia: a matched case-control study. *Arch Intern Med.* 153: 1581-6; 1993.
- [23] Shay DK, Maloney SA, Montecalvo M, et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. *J Infect Dis.* 172: 993-1000; 1995.
- [24] Clark NM, Patterson J, Lynch JP: Antimicrobial resistance among gram negative organisms in the intensive care unit. *Curr Opin Crit Care.* 9: 413-423; 2003.
- [25] Lockhart SR, Abramson MA, Beekman SE, Gallagher G, Riedel SR, Diekema DJ, Quinn JP, and Doern GV. Antimicrobial resistance among gram-negative bacilli as causes of infections in intensive care unit patients in the United States between 1993 and 2004. *J. Clin. Microbiol.* 45: 3352-3359; 2007.
- [26] Fridkin SK, Edwards JE, Tenover FC, Gaynes RP, and McGowan JE, Jr. for the Intensive Care Antimicrobial Resistance Epidemiology (ICARE) project and for National Nosocomial Infection Surveillance (NNIS) system hospitals. Antimicrobial resistance prevalence rates in hospital antibiograms reflect prevalence rates among pathogens associated with hospital-acquired infections. *Clin. Infect. Dis.* 33: 324-330; 2001.
- [27] Rhomberg PR, Fritsche TR, Sader HS, and Jones RN. Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward gram-negative isolates from meropenem yearly susceptibility test information collection program (USA). *Diagn. Microbiol. Infect. Dis.* 56: 57-62; 2006.
- [28] Roberts SA, Findlay R, Lang SDR. Investigation of an outbreak of multi-drug resistant *Acinetobacter baumannii* in an intensive care burns unit. *J Hosp Infect.* 48: 228-32; 2001.
- [29] Qureshi AH, Rafi S, Qureshi SM, Maqsood. The current susceptibility pattern of MRSA to conventional anti-staphylococcus antimicrobials at Rawalpindi. *Pak J Med Sci.* 20: 361-4; 2004.
- [30] Majeed MT, Izhar M. Glycopeptides sensitivity pattern in staphylococci isolated from clinical specimens in a tertiary care hospital. *AnnKE Med Coll.* 11: 263-7; 2005.
- [31] Cuzon G, Naas T, Nordmann P: KPC carbapenemases: what is at stake in clinical microbiology?. *Pathologie-biologie.* 58: 39-45; 2010.
- [32] Tenover FC, Arbeit RD, Goering PA, Mickelson PA, Murray BE, Persing DH, and Swaminathan B. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. *J. Clin. Microbiol.* 33: 2233-2239; 1995.
- [33] Whitney CG, Farley MM, Hadler J, Harrison LH, Lexau C, Reingold A, Lefkowitz L, Cieslak PR, Cetron M, Zell ER, Jorgensen JH, and Schuchat A for The Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. Increasing prevalence of multi-drug resistant *Streptococcus pneumoniae* in the United States. *N. Engl. J. Med.* 343: 1917-1924; 2000.
- [34] National Antimicrobial Resistance Surveillance of Thailand. <http://narst.dmsc.moph.go.th/ars/box/anti2001.htm> Access on May 9, 2003.
- [35] Gunseren F, Mamikoglu L, Ozturk S, et al. A surveillance study of antimicrobial resistance of Gram negative bacteria isolated from intensive care units in eight hospitals in turkey. *J. antimicrob. Chemother.* 43: 373-378; 1999.
- [36] Rello J, Ollendorf DA, Oster G, Vera LM, Bellm L, Redman R, et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. *Chest.* 122: 2115-21; 2002.
- [37] Cook DJ, Walter SD, Cook RJ, Griffith LE, Guyatt GH, Leasa D, et al. Incidence of and risk factors for ventilator associated pneumonia in critically ill patients. *Ann Intern Med.* 129: 433-40; 1998.
- [38] Rizvi MF, Hasan Y, Memon AR, Abdullah M, Saleem S, et al. Pattern of nosocomial infection in two intensive care units of a tertiary care hospital in Karachi. *J Coll Physicians Surg Pak.* 17: 136-9; 2007.
- [39] Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infection Surveillance System. *Crit Care Med.* 27: 887-92; 1999.